Pitrakinra, targeting the α subunit of IL-4R, thereby blocking signaling of IL-4 and IL-13, suffered from similar problems to early mepolizumab trials by testing in unselected asthma populations with no clinical efficacy. Here, IL4R is linked to asthma.